Article Text

Download PDFPDF
Efficacy of perineural versus intravenous dexmedetomidine as a peripheral nerve block adjunct: a systematic review
  1. Nasir Hussain1,
  2. Chad M Brummett2,
  3. Richard Brull3,
  4. Yousef Alghothani1,
  5. Kenneth Moran1,
  6. Tamara Sawyer4 and
  7. Faraj W Abdallah5
  1. 1 Anesthesiology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA
  2. 2 Anesthesiology, University of Michigan, Ann Arbor, Michigan, USA
  3. 3 Anesthesiology, Toronto Western Hospital, Toronto, Ontario, Canada
  4. 4 College of Medicine, Central Michigan University College of Medicine, Mount Pleasant, Michigan, USA
  5. 5 Anesthesia, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
  1. Correspondence to Dr Faraj W Abdallah, Anesthesia, University of Ottawa Faculty of Medicine, Ottawa, ON K1H 8L6, Canada; mank_abda{at}yahoo.ca

Abstract

Background Dexmedetomidine is an effective local anesthetic adjunct for peripheral nerve blocks. The intravenous route for administering dexmedetomidine has been suggested to be equally effective to the perineural route; but comparative evidence is conflicting.

Objectives This evidence-based review evaluated trials comparing the effects of intravenous to perineural dexmedetomidine on peripheral nerve block characteristics in adult surgical patients. Our primary aim was to evaluate the durations of sensory and motor blockade. Duration of analgesia, onset times of sensory and motor blockade, analgesic consumption, rest pain, and dexmedetomidine-related adverse events were evaluated as secondary outcomes.

Evidence review We sought randomized trials comparing the effects of intravenous to perineural dexmedetomidine on peripheral nerve block characteristics. The Cochrane Risk of Bias tool and the Grades of Recommendation, Assessment, Development, and Evaluation criteria was used to evaluate the quality of evidence for when an outcome was reported by at least three studies.

Results Ten studies compared intravenous and perineural dexmedetomidine in the setting of upper extremity blocks (seven), lower extremity blocks (two), and truncal block (one). The doses of dexmedetomidine supplementing long-acting local anesthetics varied between a predetermined dose (50 μg) and a weight-based dose (0.5 μg/kg–1.0 μg/kg). Clinical diversity precluded quantitative pooling; and evidence is presented as a systematic review. Compared with the intravenous route, moderate quality evidence found that perineural dexmedetomidine prolonged the duration of sensory blockade in four of six trials and motor blockade in five of seven trials. Perineural dexmedetomidine also hastened the onset of sensory and motor blockade in three of six trials. No differences were reported for the remaining outcomes; and intravenous dexmedetomidine was not superior for any outcome in any of the trials.

Conclusions Moderate quality evidence appears to suggest that intravenous dexmedetomidine is an inferior peripheral nerve block adjunct compared with perineural dexmedetomidine. Perineural dexmedetomidine is associated with longer durations and faster onset of sensory and motor blockade.

  • nerve block
  • pain
  • postoperative
  • anesthesia
  • local

Data availability statement

Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text

Footnotes

  • Twitter @drchadb, @Faraj_RegAnesth

  • Contributors All authors contributed equally to this manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests CMB is a consultant for Heron Therapeutics and Alosa Heath.

  • Provenance and peer review Not commissioned; externally peer reviewed.